To the Editor.—
The encouraging initial results from the Cholesterol-Lowering Atherosclerosis Study (CLAS)1 provide a strong impetus to larger and longer studies that can focus on different outcomes (eg, total occlusion) and quantify changes on sequential coronary angiograms. As Dr Passamani2 wrote in the editorial accompanying the report, promising areas for further research include newer lipid-lowering regimens and larger reductions in low-density lipoprotein cholesterol levels.Blankenhorn et al could usefully expand on the CLAS results in two ways: first, with additional data on the baseline comparability of the two treatment groups; and second, with additional information on the global coronary change score, the primary cardiac end point in the CLAS.The article reports on the baseline comparability of the two treatment groups for some variables in Tables 1 and 2. However, the article does not report on the baseline comparability of the two treatment groups with respect to
Fisher MR. Colestipol-Niacin Therapy and Coronary Atherosclerosis. JAMA. 1987;258(19):2695. doi:10.1001/jama.1987.03400190076019
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: